-

Hims & Hers Welcomes Anja Manuel, Foreign Policy Expert, Domestic Regulations Advisor, and Former Diplomat to its Board of Directors

Manuel joins Hims & Hers board of directors to help the company further innovate and increase access to healthcare for millions within the personalized health and wellness space

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Anja Manuel to the company’s Board of Directors. Ms. Manuel is a co-founder and principal in Rice, Hadley, Gates & Manuel LLC, a strategic consulting firm founded in 2009 that helps U.S. companies navigate international markets and regulatory issues, and a former U.S. government official.

“Anja is a remarkable leader and visionary who brings extensive experience to our board working in the areas of government relations, foreign policy, technology policy, international markets, and governance matters. Her knowledge and background, combined with that of our current directors, will further accelerate our mission to help the world feel great through the power of better health,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “As we continue to improve our access to more personalized care in the U.S. and pursue our ambitions of global expansion in the coming years, Anja’s expertise in regulation and international policy will be invaluable in our next phase of growth.”

“Hims & Hers is making a tremendous impact on the U.S. healthcare industry by improving personalized care for conditions that affect millions,” said Anja Manuel. "I look forward to helping build on the already strong foundation of this company and helping to guide how the team approaches international opportunities in the future."

In addition to co-leading RHGM LLC, Ms. Manuel is an experienced board member. She currently serves on the board of Ripple Labs, Inc., a privately held leading blockchain payments company, since 2017. She served as a director of Overseas Shipping Group, Inc., a NYSE-listed transportation company, from June 2017 to June 2023, and is a member of several advisory boards of private companies, foundations and governmental entities.

Ms. Manuel is also the Executive Director of the Aspen Strategy Group and Aspen Security Forum, a premier bi-partisan forum on foreign policy in the U.S. Additionally, she previously served as a diplomat in the U.S. State Department, as an attorney at WilmerHale, and as an investment banker at Salomon Brothers. Ms. Manuel is the author of the critically acclaimed This Brave New World: India, China and the United States, published by Simon and Schuster, and numerous articles and papers. She also lectured and was a research affiliate at Stanford University from 2009-2019, teaching courses on U.S. Foreign Policy in Asia and Technology Policy. Ms. Manuel received a B.A and M.A. in International Relations with distinction from Stanford University and a J.D. cum laude from Harvard Law School.

About Hims & Hers Health, Inc

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Contacts

Jen Treadwell
press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Jen Treadwell
press@forhims.com

More News From Hims & Hers

Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions designed to meet the specific needs and preferences of individual customers. By leveraging nearly a decade of infrastructur...

Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

SAN FRANCISCO--(BUSINESS WIRE)--Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims & Hers’ scale with GRAIL’s innovative cancer screening technology to dramatically increase access to proactive care....

Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international pa...
Back to Newsroom